NewAmsterdam Pharma Company NV Profit Margin

NewAmsterdam Pharma Company NV (NAMS) currently reports a profit margin of -3644.21% as of June 2026. That compares with -232.9% in the prior-year period — down 1464.7% year over year. That is below the sector sector average of 19.62%. Use the charts on this page to explore NewAmsterdam Pharma Company NV's profit margin history and peer comparisons.

NewAmsterdam Pharma Company NV's profit margin decreased from -232.9% to -3644.21% — a 1464.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

NewAmsterdam Pharma Company NV's profit margin of -3644.21% is lower than the its sector sector average of 19.62%. That is roughly 18674.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but NewAmsterdam Pharma Company NV's current -3644.21% should be judged against industry norms (sector average: 19.62%) and against NAMS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3644.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 19.62%. From there, open related valuation or income-statement pages for NewAmsterdam Pharma Company NV, and consider following NAMS for alerts when major investors trade the stock.